Mar 11, 2024 04:05PM

Jan 9, 2024 08:03AM

Jan 9, 2024 08:00AM

Nov 13, 2023 09:45AM

Sep 27, 2023 08:30AM

Oct 17, 2022 07:35AM

Oct 17, 2022 07:30AM NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Oct 17, 2022 07:30AM

May 5, 2022 04:14PM

May 5, 2022 04:14PM

Mar 1, 2022 04:06PM

Mar 1, 2022 04:06PM

Feb 7, 2022 08:00AM

Feb 7, 2022 08:00AM NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Feb 7, 2022 08:00AM

Mar 2, 2021 08:02AM

Mar 2, 2021 08:00AM

Mar 2, 2021 08:00AM

Feb 24, 2020 09:24AM

Feb 24, 2020 08:09AM

Feb 24, 2020 08:00AM NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement

Feb 24, 2020 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All